Cernostics: Cernostics CEO on the opportunities ahead with Castle's acquisition

The Pittsburgh-based company's lead product is Tissue Cypher, which uses artificial intelligence and spatial biology to help physicians determine who of the patients diagnosed with a type of esophageal damage, Barrett's Esophagus, will go on to develop esophageal cancer.